These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 26507832)
1. Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy. Brodie MJ CNS Drugs; 2015 Nov; 29(11):893-904. PubMed ID: 26507832 [TBL] [Abstract][Full Text] [Related]
2. Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs. Groth A; Wilke T; Borghs S; Gille P; Joeres L Ger Med Sci; 2017; 15():Doc09. PubMed ID: 28638313 [No Abstract] [Full Text] [Related]
3. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs. Brigo F; Bragazzi NL; Nardone R; Trinka E Seizure; 2016 Nov; 42():29-37. PubMed ID: 27710868 [TBL] [Abstract][Full Text] [Related]
4. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel. Rudzinski LA; Vélez-Ruiz NJ; Gedzelman ER; Mauricio EA; Shih JJ; Karakis I J Investig Med; 2016 Aug; 64(6):1087-101. PubMed ID: 27252470 [TBL] [Abstract][Full Text] [Related]
5. Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. Stephen LJ; Wishart A; Brodie MJ Epilepsy Behav; 2017 Jun; 71(Pt A):73-78. PubMed ID: 28551500 [TBL] [Abstract][Full Text] [Related]
6. Adjunctive retigabine in refractory focal epilepsy: Postmarketing experience at four tertiary epilepsy care centers in Germany. Nass RD; Kurth C; Kull A; Graf W; Kasper B; Hamer HM; Strzelczyk A; Elger CE; Steinhoff BJ; Surges R; Rosenow F Epilepsy Behav; 2016 Mar; 56():54-8. PubMed ID: 26828693 [TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Patsalos PN; Berry DJ Expert Opin Pharmacother; 2012 Apr; 13(5):699-715. PubMed ID: 22404663 [TBL] [Abstract][Full Text] [Related]
8. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel. Faulkner MA; Burke RA Expert Opin Drug Saf; 2013 Nov; 12(6):847-55. PubMed ID: 23883095 [TBL] [Abstract][Full Text] [Related]
9. Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy. Li-Na Z; Deng C; Hai-Jiao W; Da X; Ge T; Ling L Epilepsy Res; 2018 Jan; 139():60-72. PubMed ID: 29197667 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures. Tompson DJ; Crean CS; Reeve R; Berry NS Clin Ther; 2013 Aug; 35(8):1174-1185.e4. PubMed ID: 23916044 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study. Lim KS; Lotay N; White R; Kwan P Epilepsy Behav; 2016 Aug; 61():224-230. PubMed ID: 27376872 [TBL] [Abstract][Full Text] [Related]
12. Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment. Kwok CS; Johnson EL; Krauss GL CNS Drugs; 2017 Nov; 31(11):959-974. PubMed ID: 29204953 [TBL] [Abstract][Full Text] [Related]
13. Ezogabine: a novel antiepileptic as adjunctive therapy for partial onset seizures. Owen RT Drugs Today (Barc); 2010 Nov; 46(11):815-22. PubMed ID: 21225020 [TBL] [Abstract][Full Text] [Related]
14. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study. Runge U; Arnold S; Brandt C; Reinhardt F; Kühn F; Isensee K; Ramirez F; Dedeken P; Lauterbach T; Noack-Rink M; Mayer T Epilepsia; 2015 Dec; 56(12):1921-30. PubMed ID: 26526971 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients with severely refractory epilepsies - A monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center. Kurth C; Kockelmann E; Steinhoff BJ Seizure; 2017 Feb; 45():47-51. PubMed ID: 27915111 [TBL] [Abstract][Full Text] [Related]
16. Recent and future antiepileptic drugs and their impact on cognition: what can we expect? Mula M Expert Rev Neurother; 2012 Jun; 12(6):667-71. PubMed ID: 22650169 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study. Toupin JF; Lortie A; Major P; Diadori P; Vanasse M; Rossignol E; D'Anjou G; Perreault S; Larbrisseau A; Carmant L; Birca A Epileptic Disord; 2015 Dec; 17(4):436-43. PubMed ID: 26609635 [TBL] [Abstract][Full Text] [Related]
19. Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability. Brodie MJ; French JA; McDonald SA; Lee WJ; Adams B; Scott A; Nohria V; DeRossett S Epilepsy Res; 2014 Jul; 108(5):989-94. PubMed ID: 24726452 [TBL] [Abstract][Full Text] [Related]